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abstract
A previous study showed that, in carriers of the apolipoprotein E (APOE) genotype ε3/ε3o rε3/ε4, the
presence of a very long (VL) polyT repeat allele in “translocase of outer mitochondrial membrane 40”
(TOMM40) was less frequent in patients with sporadic inclusion body myositis (sIBM) compared with
controls and associated with a later age of sIBM symptom onset, suggesting a protective effect of this
haplotype. To further investigate the inﬂuence of these genetic factors in sIBM, we analyzed a large sIBM
cohort of 158 cases as part of an International sIBM Genetics Study. No signiﬁcant association was found
between APOE or TOMM40 genotypes and the risk of developing sIBM. We found that the presence of at
least 1 VL polyT repeat allele in TOMM40 was signiﬁcantly associated with about 4 years later onset of
sIBM symptoms. The age of onset was delayed by 5 years when the patients were also carriers of the
APOE genotype ε3/ε3. In addition, males were likely to have a later age of onset than females. Therefore,
the TOMM40 VL polyT repeat, although not inﬂuencing disease susceptibility, has a disease-modifying
effect on sIBM, which can be enhanced by the APOE genotype ε3/ε3.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Sporadic inclusion body myositis (sIBM) is known as the most
common acquired myopathy among people 50 years and older
(Machado et al., 2014). Given its similarities with Alzheimer’s
disease such as the late age of onset and the abnormal accumula-
tion of proteins, the apolipoprotein E (APOE, OMIM#107741) gene
has been one of the most popular genes studied in sIBM (Ganget al.,
2014), but no association with sIBM disease risk was conﬁrmed
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Neurobiology of Aging 36 (2015) 1766.e1e1766.e3(Needham et al., 2008). Recently, the “translocase of outer
mitochondrial membrane 40” (TOMM40, OMIM#608061) gene,
which is adjacent to and in strong linkage disequilibrium with the
APOE locus on chromosome 19, has been studied in 90 Caucasian
patients with sIBM (Mastaglia et al., 2013). That study reported that
among carriers of the APOE genotype ε3/ε3o rε3/ε4, carriage of a
very long (VL) polyT repeats in the intron 6 of TOMM40
(rs10527454) was less frequent in sIBMcomparedwithcontrols and
was also associated with a later age of onset of sIBM symptoms
(Mastaglia et al., 2013). To further investigate the previously
reported association between APOE-TOMM40 and sIBM, we geno-
typed APOE and the polyT repeat polymorphism in TOMM40 in a
large sIBM cohort of 158 affected cases from the International IBM
Genetics Consortium and investigated their association with dis-
ease risk and the age of onset of sIBM.
2. Methods
Atotalof158DNAsamplesfrombiopsy-conﬁrmedsIBMpatients
(66.5% males) were collected from 9 centres around the world. The
control group comprised 127 individuals with no history of neuro-
muscular disease. Restriction fragment length polymorphism was
used for APOE genotyping. Fluorescence-based fragment size anal-
ysiswasperformedforgenotypingthepolyTrepeatinintron6ofthe
TOMM40gene(rs10527454).ThepolyTrepeatalleleswereclassiﬁed
based on the length of repeat (N) as originally established by Roses
et al. (2010). Genotypic frequencies for APOE and TOMM40 polyT
were compared between cases and controls using the chi-square or
the Fisher’s exact test. The associations between APOE genotypes,
TOMM40polyTgenotypes,ethnicity,gender,andageofonsetofsIBM
were analyzed by linear regression analyses. For all the analyses,
pvalue<0.05wasconsideredstatisticallysigniﬁcant(fordetails,see
Supplementary Data).
3. Results
The APOE ε2/ε2 genotype was absent in both the sIBM cohort
and the control group. No signiﬁcant differences were found
between patients and controls regarding APOE allelic and genotypic
frequencies, considering neither only Caucasian patients nor the
entire cohort. The distribution of TOMM40 polyTrepeat lengths was
similar in the sIBM group (range 8e36 repeats) and controls (11e33
repeats) (Supplementary Fig. 1). The frequency of neither TOMM40
polyT repeat genotypes nor polyT alleles differed signiﬁcantly
between groups (Supplementary Table 1). When the analysis was
performed in the combined group of carriers of ε3/ε3 and ε3/ε4
APOE genotypes, there was still no association between of the
presence of VL polyT repeats and sIBM risk (Supplementary
Table 2).
There was no signiﬁcant association between different APOE
alleles and the age of onset of sIBM. However, being a carrier of the
polyT repeat, VL allele was signiﬁcantly associated with a later age
of onset by 3.7 years in average (95% conﬁdence interval [CI] ¼ 0.4,
6.9; adjusted p ¼ 0.027). We repeated the analysis just forcarriers of
the APOE ε3/ε3 genotype. We found that APOE ε3-TOMM40 VL allele
carriers had an even later age of onset of sIBM by 4.9 years in
average (95% CI ¼ 1.1, 8.7; adjusted p ¼ 0.013). Similar results were
found when the analysis was restricted to Caucasians (by 4.0 years
for a VL carriage, 95% CI ¼ 0.4, 7.6; p ¼ 0.028; by 5.4 years for car-
riage of a VL allele and APOE ε3/ε3 genotype, 95% CI ¼ 1.2, 9.7;
p ¼ 0.013). Although not reaching statistical signiﬁcance, there was
also a trend for a later age of onset (by 2.7 years) in males compared
with females (Table 1).
4. Discussion
This is the largest cohort where the inﬂuence of the APOE and
TOMM40 genes in sIBM disease risk and features has been inves-
tigated. Concerning APOE, our ﬁndings conﬁrmed that the APOE ε4
allele is not a susceptibility factor for developing sIBM, which is
consistent with the previous studies (Needham et al., 2008). APOE
alleles were also not signiﬁcantlyassociated with the ageof onset of
the disease. In addition, our ﬁndings did not replicate a previously
reported association between APOE-TOMM40 and risk of devel-
oping sIBM (Mastaglia et al., 2013). However, we observed that
carriage of a VL repeat allele was signiﬁcantly associated with a
later age of onset of symptoms. This effect was even more pro-
nounced among those also with the APOE ε3/ε3 genotype. This
suggests that the TOMM40 VL polyT repeat has a disease-modifying
effect on sIBM by delaying the onset of symptoms, and the APOE ε3/
ε3 genotype enhances this effect. Although the association between
APOE and TOMM40 and sIBM risk was not conﬁrmed in our study,
the ﬁnding of an association between the TOMM40 VL polyT repeat
and a later age of onset of sIBM may justify further gene expression
studies in the future. In addition, there might be other variants
within the APOE-TOMM40 locus involved in the susceptibility to
sIBM. Furthermore, identiﬁcation of new genes and variants is
crucial to improve our understanding of this complex disease.
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Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.neurobiolaging.
2014.12.039.
Table 1
Inﬂuences of APOE alleles, TOMM40 polyT repeat of VL length, ethnicity, and gender
on the age of onset of sIBM using standard adjusted linear regression analysis
Variable Count Age of onset
(mean   SD), y
Adjusted analysis
a
Regression coefﬁcient
(95% CI)
p Value
b
Ethnicity
Non-Caucasian 16 56.7   5.7 Reference
Caucasian 141 60.0   10.0 2.8 ( 2.3, 7.9) 0.28
Gender
F 52 57.9   10.4 Reference
M 105 60.6   9.3 2.7 ( 0.5, 5.9) 0.095
APOE
ε2/ε4
c 6 56.8   5.8
ε3/ε3 99 60.2   9.8 Reference
ε2/ε3 19 56.9   10.0  2.9 ( 7.7, 1.9) 0.23
ε3/ε4 and ε4/ε4 33 60.4   9.7 1.6 ( 2.4, 5.7) 0.43
TOMM40 polyT
No VL carriage 74 58.1   9.7 Reference
VL carriage 83 61.2   9.6 3.7 (0.4, 6.9) 0.027
APOE-TOMM40
ε3/ε3 and polyT
non-VL carriage
38 57.3   9.9 Reference
ε3/ε3 and polyT
VL carriage
61 62.0   9.4 4.9 (1.1, 8.7) 0.013
Key: APOE, apolipoprotein E; CI, conﬁdence interval; F, female; M, male; SD,
standard deviation, sIBM, sporadic inclusion body myositis; TOMM40, translocase of
outer mitochondrial membrane 40; VL, very long.
a Each analysis was adjusted for gender, ethnicity, tissue, and genetic factors,
except for the variable under study.
b p value < 0.05 was considered statistically signiﬁcant (marked in bold).
c ε2/ε4 was not included in the regression analysis for APOE alleles and the age of
onset.
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